Volume 36, Issue 2 (6-2025)
Studies in Medical Sciences 2025, 36(2): 131-136 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fatahi F, Morovati Sharif Abad M, Salehi E, Dehestani Ardakani M, Rezaei-Golmisheh A. Effect of Paxlovid on Liver Morphogenesis in Animal Model Embryo (Rat). Studies in Medical Sciences 2025; 36 (2) :131-136
URL: http://umj.umsu.ac.ir/article-1-6432-en.html
URL: http://umj.umsu.ac.ir/article-1-6432-en.html
Fatemeh Fatahi 
, Majid Morovati Sharif Abad * 
, Elham Salehi , Mahin Dehestani Ardakani , Ali Rezaei-Golmisheh
, Majid Morovati Sharif Abad * , Elham Salehi , Mahin Dehestani Ardakani , Ali Rezaei-Golmisheh
Department of Basic Science, Faculty of Veterinary Medicine, Ardakan University, Ardakan, Iran , mmorovati@ardakan.ac.ir
Abstract: (241 Views)
Background The antiviral drug Paxlovid has been approved for the treatment of COVID-19 in adult patients. This study aimed to investigate the potential effects of Paxlovid administration on liver morphogenesis in rat embryos.
Methods Pregnant rats were randomly assigned to four groups (n = 10 per group): a control group (vehicle), experimental group one (Paxlovid 60 and 100 mg/kg), experimental group two (Paxlovid 200 and 300 mg/kg), and experimental group three (Paxlovid 1000 mg/kg). The Animals were treated daily via oral gavage. Maternal body weight was recorded on gestational days seven, 14, and 21. On gestational day 17, blood samples were collected from five animals in each group at five different time points. Paxlovid concentrations in the serum samples were quantified using high-performance liquid chromatography.
Results The results showed no structural changes in liver tissue. However, the maternal body weight on day 21 of pregnancy was significantly lower in experimental group one compared with the control group (p < 0.05). Fetal weight in all three experimental groups was significantly reduced compared with the control group. In addition, crown–rump length and abdominal circumference in experimental groups one and two were significantly decreased compared with the control group (p < 0.05). Measurement of systemic drug concentration indicated that experimental group two had the highest level of drug absorption, while experimental group three showed the lowest absorption.
Conclusion Overall, our findings indicate that although Paxlovid, at the investigated doses, may affect maternal weight and fetal growth parameters, it does not induce morphological or histological abnormalities in the fetal rat liver.
Methods Pregnant rats were randomly assigned to four groups (n = 10 per group): a control group (vehicle), experimental group one (Paxlovid 60 and 100 mg/kg), experimental group two (Paxlovid 200 and 300 mg/kg), and experimental group three (Paxlovid 1000 mg/kg). The Animals were treated daily via oral gavage. Maternal body weight was recorded on gestational days seven, 14, and 21. On gestational day 17, blood samples were collected from five animals in each group at five different time points. Paxlovid concentrations in the serum samples were quantified using high-performance liquid chromatography.
Results The results showed no structural changes in liver tissue. However, the maternal body weight on day 21 of pregnancy was significantly lower in experimental group one compared with the control group (p < 0.05). Fetal weight in all three experimental groups was significantly reduced compared with the control group. In addition, crown–rump length and abdominal circumference in experimental groups one and two were significantly decreased compared with the control group (p < 0.05). Measurement of systemic drug concentration indicated that experimental group two had the highest level of drug absorption, while experimental group three showed the lowest absorption.
Conclusion Overall, our findings indicate that although Paxlovid, at the investigated doses, may affect maternal weight and fetal growth parameters, it does not induce morphological or histological abnormalities in the fetal rat liver.
Type of Study: Research |
Subject:
جنین شناسی
References
1. Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, et al. Liver cell type-specific targeting by nanoformulations for therapeutic applications. Int J Mol Sci. 2023;24(14):11869. [DOI:10.3390/ijms241411869] [PMID] []
2. Wang X, Yang L, Wang Y-C, Xu Z-R, Feng Y, Zhang J, et al. Comparative analysis of cell lineage differentiation during hepatogenesis in humans and mice at the single-cell transcriptome level. Cell Res. 2020;30(12):1109-26. [DOI:10.1038/s41422-020-0378-6] [PMID] []
3. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev. 2004;14(5):582-90. [DOI:10.1016/j.gde.2004.08.004] [PMID]
4. Tremblay KD, Zaret KS. Distinct populations of endoderm cells converge to generate the embryonic liver bud and ventral foregut tissues. Dev Biol. 2005;280(1):87-99. [DOI:10.1016/j.ydbio.2005.01.003] [PMID]
5. Xu J, Hao S, Shi Q, Deng Q, Jiang Y, Guo P, et al. Transcriptomic profile of the mouse postnatal liver development by single-nucleus RNA sequencing. Front. Cell Dev.Biol. 2022;10:833392. [DOI:10.3389/fcell.2022.833392] [PMID] []
6. Ober EA, Lemaigre FP. Development of the liver: Insights into organ and tissue morphogenesis. J Hepatol. 2018;68(5):1049-62. [DOI:10.1016/j.jhep.2018.01.005] [PMID]
7. Akinosoglou K, Schinas G, Gogos C. Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir. Viruses. 2022;14(11):2540. [DOI:10.3390/v14112540] [PMID] []
8. Amani, B., & Amani, B. (2023). Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis. J. Med Virol, 95(2), e28441. [DOI:10.1002/jmv.28441] [PMID] []
9. Hashemian SMR, Sheida A, Taghizadieh M, Memar MY, Hamblin MR, Baghi HB, et al. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed Pharmacother. 2023;162:114367. [DOI:10.1016/j.biopha.2023.114367] [PMID] []
10. McCarthy MW. McCarthy MW. Optimizing the use of Paxlovid in clinical practice. Drugs Today (Barc). 2022;58(11):539-546. [DOI:10.1358/dot.2022.58.11.3461265] [PMID]
11. Catlin N, Bowman C, Campion S, Cheung J, Nowland W, Sathish J, et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Reprod Toxicol. 2022;108:56-61. [DOI:10.1016/j.reprotox.2022.01.006] [PMID] []
12. Bege M, Borbás A. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19. Pharm. 2024;16(2):217. [DOI:10.3390/pharmaceutics16020217] [PMID] []
13. Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585-91. [DOI:10.1007/s40265-022-01692-5] [PMID] []
14. Imam MS, Batubara AS, Gamal M, Abdelazim AH, Almrasy AA, Ramzy S. Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations. Sci Rep. 2023;13(1):137. [DOI:10.1038/s41598-022-26944-y] [PMID] []
15. Pasley MV, Martinez M, Hermes A, d'Amico R, Nilius A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev. 2013;15(1):38-48. [GOOGLE SCHOLAR]
16. Vangelotti A, Júnior EA, Simões M, Amed A, Nakamura M, Júnior LK. Chronic action of lamivudine and ritonavir on maternal and fetal liver and kidney of albino pregnant rats (Rattus norvegicus albinus, Rodentia, Mammalia): morphological and biochemical aspects. Clin Exp Obstet Gynecol. 2015;42(4):523-8. [DOI:10.12891/ceog1885.2015] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
